CLINICAL TRIALS PROFILE FOR CHLORPROMAZINE HYDROCHLORIDE

All Clinical Trials for Chlorpromazine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00122278 ↗	Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines	Completed	Montefiore Medical Center	Phase 3	2005-07-01	Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard ER therapy will help patients get better quicker and stay pain-free more often than if they receive placebo.
NCT00140179 ↗	Valnoctamide in Mania	Completed	Stanley Medical Research Institute	Phase 3	2004-09-01	Valproic acid is a leading mood stabilizer for the treatment of bipolar disorder. Its well-known teratogenicity limits its use in young women of childbearing age. According to toxicologic studies the teratogenicity of valproate stems from its free carboxylic group. Valnoctamide is an isomer and an analog of valpromide. Unlike valpromide, valnoctamide does not undergo a biotransformation to the corresponding free acid. It is also likely or at least possible that valnoctamide is anti-bipolar. In mice valnoctamide has been shown to be distinctly less teratogenic than valproate. An injection at day 8 of gestation produced only 1% exencephaly (as compared to 0-1% in control mice and 53% in valproate treated mice). The investigators are performing a double-blind controlled trial of valnoctamide as an anti-bipolar drug. If shown to be anti-bipolar, valnoctamide could be an important valproate substitute for young women with bipolar disorder who are at risk of pregnancy. Patients newly admitted to the Beersheva Mental Health Center may participate if they meet Diagnostic and Statistical Manual of Mental Disorders - 4th edition (DSM-IV) criteria for mania or schizoaffective disorder, manic type. Patients admitted to the study are treated with risperidone at doses of the physicians' discretion beginning with 2 mg daily on days 1 and 2. Valnoctamide or placebo is begun at doses of 600 mg per day (200 mg three times daily) and increased to 1200 mg (400 mg three times daily) after four days. Weekly ratings by a psychiatrist blind to the study drug are conducted using the Brief Psychiatric Rating Scale (BPRS), the Young Mania Rating Scale (YMS), and the Clinical Global Impression (CGI). Weekly blood is drawn for drug levels of valnoctamide to be measured by gas chromatography. Each patient receives valnoctamide or placebo for 5 weeks. Low teratogenic mood stabilizers are a high priority for current research.
NCT00140179 ↗	Valnoctamide in Mania	Completed	Beersheva Mental Health Center	Phase 3	2004-09-01	Valproic acid is a leading mood stabilizer for the treatment of bipolar disorder. Its well-known teratogenicity limits its use in young women of childbearing age. According to toxicologic studies the teratogenicity of valproate stems from its free carboxylic group. Valnoctamide is an isomer and an analog of valpromide. Unlike valpromide, valnoctamide does not undergo a biotransformation to the corresponding free acid. It is also likely or at least possible that valnoctamide is anti-bipolar. In mice valnoctamide has been shown to be distinctly less teratogenic than valproate. An injection at day 8 of gestation produced only 1% exencephaly (as compared to 0-1% in control mice and 53% in valproate treated mice). The investigators are performing a double-blind controlled trial of valnoctamide as an anti-bipolar drug. If shown to be anti-bipolar, valnoctamide could be an important valproate substitute for young women with bipolar disorder who are at risk of pregnancy. Patients newly admitted to the Beersheva Mental Health Center may participate if they meet Diagnostic and Statistical Manual of Mental Disorders - 4th edition (DSM-IV) criteria for mania or schizoaffective disorder, manic type. Patients admitted to the study are treated with risperidone at doses of the physicians' discretion beginning with 2 mg daily on days 1 and 2. Valnoctamide or placebo is begun at doses of 600 mg per day (200 mg three times daily) and increased to 1200 mg (400 mg three times daily) after four days. Weekly ratings by a psychiatrist blind to the study drug are conducted using the Brief Psychiatric Rating Scale (BPRS), the Young Mania Rating Scale (YMS), and the Clinical Global Impression (CGI). Weekly blood is drawn for drug levels of valnoctamide to be measured by gas chromatography. Each patient receives valnoctamide or placebo for 5 weeks. Low teratogenic mood stabilizers are a high priority for current research.
NCT00169039 ↗	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia	Terminated	Commonwealth Research Center, Massachusetts	Phase 4	1994-12-01	This study will examine the physical response to clozapine or chlorpromazine in people with schizophrenia that has not improved with treatment.
NCT00169039 ↗	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia	Terminated	Dartmouth-Hitchcock Medical Center	Phase 4	1994-12-01	This study will examine the physical response to clozapine or chlorpromazine in people with schizophrenia that has not improved with treatment.
NCT00169039 ↗	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia	Terminated	National Institute of Mental Health (NIMH)	Phase 4	1994-12-01	This study will examine the physical response to clozapine or chlorpromazine in people with schizophrenia that has not improved with treatment.

Clinical Trial Conditions for Chlorpromazine Hydrochloride

Condition Name

Condition Name for Chlorpromazine Hydrochloride
Intervention	Trials
Schizophrenia	13
Schizoaffective Disorder	6
Bipolar Disorder	3
Schizophreniform Disorder	3

Condition MeSH

Condition MeSH for Chlorpromazine Hydrochloride
Intervention	Trials
Schizophrenia	16
Psychotic Disorders	10
Disease	6
Mental Disorders	6

Clinical Trial Locations for Chlorpromazine Hydrochloride

Trials by Country

Trials by Country for Chlorpromazine Hydrochloride
Location	Trials
United States	32
China	13
Spain	9
Taiwan	3
Canada	3

Trials by US State

Trials by US State for Chlorpromazine Hydrochloride
Location	Trials
Texas	4
New York	4
Ohio	2
Iowa	1
Washington	1

Clinical Trial Progress for Chlorpromazine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Chlorpromazine Hydrochloride
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	1
Phase 4	9

Clinical Trial Status

Clinical Trial Status for Chlorpromazine Hydrochloride
Clinical Trial Phase	Trials
Completed	21
Not yet recruiting	5
Unknown status	5

Clinical Trial Sponsors for Chlorpromazine Hydrochloride

Sponsor Name

Sponsor Name for Chlorpromazine Hydrochloride
Sponsor	Trials
Stanley Medical Research Institute	2
Capital Medical University	2
Centre for Addiction and Mental Health	2

Sponsor Type

Sponsor Type for Chlorpromazine Hydrochloride
Sponsor	Trials
Other	65
Industry	7
NIH	4

Chlorpromazine Hydrochloride: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 27, 2026

What is chlorpromazine hydrochloride’s current clinical-trials footprint?

Chlorpromazine hydrochloride is a first-generation antipsychotic with a long clinical record, spanning schizophrenia and other psychotic disorders, bipolar mania, and off-label uses such as agitation and nausea in some jurisdictions. Trial activity in recent years is dominated by investigator-initiated or small-company studies focused on comparative effectiveness, formulation, regimen optimization, and safety monitoring rather than de novo phase-3 programs that typically define modern late-stage pipelines.

Which clinical trial themes show up most often in recent registrations and updates?

Across recent trial registries, the recurring themes for chlorpromazine studies are consistent with an “evidence extension” model:

• Comparative effectiveness: head-to-head or add-on comparisons against other antipsychotics or antiemetic regimens in defined clinical settings.
• Safety and tolerability monitoring: metabolic parameters, QTc-related monitoring, extrapyramidal symptoms, and sedation-related endpoints.
• Dose and regimen optimization: short-interval titration, route-of-administration comparisons, and practical dosing schedules aligned to local formularies.
• Special populations: studies in contexts where clinicians focus on tolerability and adverse-event management.

Chlorpromazine’s trial profile is shaped by its status as an established generic product in most major markets, which reduces incentives for large, brand-like phase-3 development and shifts activity toward smaller clinical studies and pharmacovigilance-style evidence.

How to interpret the practical “clinical trials update” for a commercially oriented view

For business and investment decisions, the key read-through is that chlorpromazine’s clinical development is not currently characterized by a single blockbuster global late-stage program. The more decision-relevant signal is whether specific jurisdictions sponsor new comparative data or formulation trials that can support formulary positioning, guideline updates, or switch programs away from competing agents in target indications.

What is the market structure for chlorpromazine hydrochloride today?

Chlorpromazine hydrochloride is marketed as a generic in most high-income markets. The competitive landscape is driven by:

• Low unit prices
• High supply from multiple manufacturers
• Formulary access via health systems and national procurement
• Therapeutic substitution within antipsychotic classes

This structure generally limits premium pricing power and reduces the ability for new entrants to differentiate on clinical novelty alone.

Market demand drivers

• Chronic psychosis management: where chlorpromazine remains a low-cost option or is selected based on clinical practice patterns.
• Acute management protocols: in some settings, clinicians use chlorpromazine for agitation or behavioral control where protocols align.
• Antiemetic and perioperative nausea pathways: in certain healthcare systems and formularies, chlorpromazine supports nausea and vomiting management strategies.
• Off-label use persistence: established clinician preference sustains baseline demand even when newer agents dominate some lines of therapy.

Competitive set

Chlorpromazine competes indirectly with:

• Other first-generation antipsychotics (e.g., haloperidol, thioridazine where available)
• Second-generation antipsychotics (e.g., risperidone, olanzapine, quetiapine, aripiprazole) in schizophrenia and bipolar indications
• Antiemetic alternatives (dopamine antagonists and serotonin antagonists) for nausea pathways

In practice, chlorpromazine’s purchasing advantage is cost and availability rather than differentiated efficacy.

What is the pricing and volume reality for generics like chlorpromazine?

For generics, market outcomes tend to hinge on:

• Tender/contract outcomes in national and regional procurement
• Inventory reliability and supply chain resilience
• Formulation availability (tablet, concentrate/solution, injectable formats where used)
• Local reimbursement and formulary inclusion

Because chlorpromazine is off-patent, the market behaves like a mature commodity. Price erosion and share shifts are common when additional suppliers enter or when procurement consolidates.

Market sizing and projection framework (business-operational)

A precise numeric market projection for chlorpromazine hydrochloride requires jurisdiction-level sales, unit consumption data, and manufacturer/wholesale pricing history. Without those inputs, the only defensible projection is directional and framework-based:

Base case projection (directional)

• Demand: stable to modestly growing globally, supported by persistent clinical use and cost-driven positioning in lower-income and resource-constrained healthcare settings.
• Revenue: typically flat to declining at a unit-price level in mature generic markets due to ongoing price competition.
• Share: tied to procurement and product availability, with supplier churn risks when contracts rotate.

Upside scenarios

• Formulary reinstatement or expanded use in specific indications where comparative or real-world evidence favors chlorpromazine in cost-effectiveness terms.
• Protocol-driven re-adoption in acute agitation or specific inpatient pathways where clinicians prefer its sedation profile and administration routes.
• Manufacturing expansion in regions with supply gaps that strengthen availability and contract awards.

Downside scenarios

• Protocol shift toward second-generation agents for chronic psychosis where payers prefer their safety profiles for certain patient subsets.
• Regulatory or safety-driven prescribing constraints (for example, QTc-related cautions and increased monitoring burden) that reduce routine prescribing intensity.
• Procurement consolidation that pressures margins for all suppliers, triggering further price erosion.

How do patent and exclusivity constraints shape the future?

Chlorpromazine hydrochloride’s global development is constrained by its generic status. Near-term commercial upside does not come from new chemical entity exclusivity but from:

• Lifecycle management tied to formulation (e.g., modified-release or improved delivery)
• Regulatory filings that support substitution and market access
• Evidence generation that improves guideline alignment in specific jurisdictions

For investment and R&D planning, the commercial ceiling for “new entrants” is usually limited by generic competition unless differentiation is achieved through formulation, device-like delivery, or specific patient-management systems that payers recognize.

What R&D pathways are most aligned with a chlorpromazine business case?

Given generic saturation, only certain trial types create tangible commercial value:

• Formulation trials that change administration convenience, reduce administration error, or improve tolerability through dosing form.
• Comparative protocol trials that support payer or guideline adoption in cost-effectiveness frameworks.
• Safety monitoring studies that quantify QTc, sedation burden, and extrapyramidal symptoms in real-world settings to support risk management.

These approaches can influence uptake in tenders and clinical protocols, even when the active ingredient remains off-patent.

---

Key Takeaways

• Chlorpromazine hydrochloride’s modern “clinical trials update” is dominated by smaller evidence-generation and regimen/safety-focused studies rather than major late-stage global phase-3 programs.
• The market is mature and commodity-like: pricing is driven by generic supply and procurement, while growth depends on formulary inclusion and regional prescribing patterns.
• Revenue growth is likely to be limited by ongoing price pressure; demand is more likely to be stable than rapidly expanding.
• The most commercially relevant R&D for chlorpromazine centers on formulation and protocol evidence that strengthens access through tenders, formularies, and guideline alignment.

FAQs

1. Is chlorpromazine hydrochloride currently under active late-stage phase-3 development globally?
   No clear global pattern of large, brand-scale phase-3 trials defines the recent landscape; activity typically reflects evidence extension, regimen work, and safety monitoring.

2. What indications most consistently support chlorpromazine use?
   Psychosis-related indications such as schizophrenia and bipolar mania are the core use cases, with off-label practice sustaining demand in selected settings.

3. What drives chlorpromazine sales most in mature markets?
   Procurement contracts, formulary inclusion, and product availability (including dosage form and route) drive commercial outcomes more than incremental clinical differentiation.

4. How does generic competition affect pricing and margins?
   It compresses pricing and increases supplier churn risk; revenue typically tracks usage volumes less than unit pricing erosion.

5. What trial evidence would matter most for future uptake?
   Comparative protocol outcomes, safety-risk quantification (QTc, EPS, sedation burden), and formulation usability endpoints that influence prescribing decisions and payer acceptance.

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Chlorpromazine hydrochloride search results. https://clinicaltrials.gov/
[2] World Health Organization. WHO Model List of Essential Medicines. (Latest edition listing chlorpromazine where applicable). https://www.who.int/teams/health-product-and-policy-standards/standardization-and-specifications/essential-medicines
[3] DailyMed. Chlorpromazine hydrochloride drug label information. https://dailymed.nlm.nih.gov/